Assessing the Utility of the Aspartate Aminotransferase to Platelet Ratio Index (APRI) as a Noninvasive Indicator for...

Area of Science:

• Hepatology
• Diagnostic markers
• Noninvasive assessment

Background:

• Cirrhosis is a leading cause of death globally, necessitating effective diagnostic tools.
• Advanced liver fibrosis poses a significant public health challenge.
• Noninvasive methods for assessing liver fibrosis are crucial for patient management.

Purpose of the Study:

• To evaluate the efficacy of the Aspartate Aminotransferase to Platelet Ratio Index (APRI) in diagnosing liver cirrhosis.
• To determine the prognostic value of APRI in patients with liver disease.

Main Methods:

• A prospective observational study involving 100 cases and 100 controls with liver disease.
• Collection of sociodemographic, clinical, and laboratory data, including prothrombin time, liver function tests, and complete blood count.
• Statistical analysis to compare patient and control groups and assess APRI's diagnostic accuracy.

Main Results:

• Significant differences in activated partial thromboplastin time (aPTT) and liver function tests (SGOT, SGPT) were observed between patients and controls.
• A statistically significant variation in APRI distribution was found between the study groups.
• The ideal APRI cutoff for diagnosing cirrhosis was 3.99, with a sensitivity of 33% and specificity of 86%.

Conclusions:

• APRI serves as a crucial noninvasive prognostic tool for liver cirrhosis.
• The study supports the utility of APRI in prognosticating liver cirrhosis.
• Further research may refine APRI's role in clinical practice for liver disease management.